---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-115681"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2021-09-15T23:59:59+00:00"
generated_at: "2026-06-29T03:32:23.749755+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Theravance cuts 75% of staff; ampreloxetine Phase 3 misses primary endpoint

## Summary
- Headcount reduction of ~75% (~270 positions); most complete Nov 2021, remainder Feb 2022.
- Estimated $165M annualized operating expense savings in 2022; expects cash flow positive from 2H 2022.
- Ampreloxetine Phase 3 study (0169) failed to meet primary endpoint; no safety concerns.
- EVP & General Counsel Shafer resigns; SVP Sabesan leaves Nov 30; two directors (Whitesides, Gunderson) resign.

## SEC filing metadata
- accession: 0001104659-21-115681
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2021-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/tm2127424d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-115681
- JSON: https://secwatch.observer/filing/0001104659-21-115681.json
- Plain text: https://secwatch.observer/filing/0001104659-21-115681.txt

## Key facts
- Executive change
  Vijay Sabesan departed as Senior Vice President, Technical Operations at Theravance Biopharma, Inc..
  - Action: departed
  - Role: Senior Vice President, Technical Operations
  source text: Vijay Sabesan, Senior Vice President, Technical Operations, a “named executive officer” from 2021, will leave the Company on November 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm
- Executive change
  Robert V. Gunderson, Jr. resigned as Director at Theravance Biopharma, Inc..
  - Action: resigned
  - Role: Director
  source text: Robert V. Gunderson, Jr. notified the Company of his resignation as a Director of the Company effective September 11, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm
- Executive change
  Braford J. Shafer resigned as Executive Vice President and General Counsel at Theravance Biopharma, Inc..
  - Action: resigned
  - Role: Executive Vice President and General Counsel
  source text: On September 13, 2021, Braford J. Shafer, a “named executive officer” from 2021, notified the Company of his resignation as its Executive Vice President and General Counsel effective on September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm
- Executive change
  George M. Whitesides resigned as Director at Theravance Biopharma, Inc..
  - Action: resigned
  - Role: Director
  source text: George M. Whitesides notified the Company of his resignation as a Director of the Company effective September 14, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465921115681/0001104659-21-115681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.